HuM&C휴엠앤씨

HuM&C's trailing profits are thin and the share price has fallen sharply over the past year, while filings show ongoing legal matters and a share buyback trust that was terminated.

HuM&C makes glass containers for pharmaceutical injectables and cosmetics accessories, sold business-to-business. Trailing twelve-month revenue to H1 2026 was ₩56.5B with operating income of ₩3.3B, and the shares closed at ₩2,890 on 2026-10-21, down about 34% over one year. The data shows a company past a loss-making 2021 and a strong 2023 net income year, but with recent profit well below that peak.

What stands out

• Trailing revenue is ₩56.5B and net income is ₩3.2B, a 5.6% net margin, against 2025 annual net income of ₩1.6B.
• 2023 net income of ₩10.3B looks inflated relative to operating income of ₩4.8B, and the data does not explain the gap.
• The stock trades at about 8.9x earnings and 0.6x book value, with a 6.9% dividend yield shown in the data.
• The company's own fair value model gives a base value of ₩4,547, but this is an internal model output, not a forecast or recommendation.
• Recent filings include repeated updates on embezzlement and breach of trust allegations, and a buyback trust contract that was later terminated.

What to watch

• Next quarterly and annual filings, to see whether operating margin holds near the 5.8% trailing level.
• Progress on the embezzlement and breach of trust allegations named in the filings, which the data does not describe in detail.
• Foreign ownership fell from 0.9% to 0.7% over 60 days; no recent news headlines were available in the data.